News from Zyme and the companies we work with.
Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from all existing investors Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in [...]
Asimov launches LV Edge Packaging System to optimize lentivirus production
New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk. System achieves [...]
Cellular Origins, a TTP Company, appoints Peter Crossley as Chief Operating Officer
Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scale CAMBRIDGE, UK, 25 January 2024: Cellular Origins, [...]
CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies
Strategic partnership harnesses respective organ-specific expertise to provide complete human-derived Organ-on-a-Chip solution for more accurate in vitro ADME predictions Early access to dual-organ model available through CN Bio’s Contract Research [...]
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN [...]
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases New company to complete multiple clinical [...]
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness Dublin, Ireland, and Tampere, Finland, 17 January 2024: ERS Genomics Limited [...]
Cellular Origins, a TTP Company, establishes Advisory Board of global industry leaders
Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives Cambridge, UK, [...]
Metrion Biosciences closes £3.7m new equity financing
Financing led by Maven Capital Partners, alongside Gresham House Ventures Funds to be used to expand Metrion’s Cambridge UK laboratories and to enhance scientific and commercial capabilities Dr David Milroy [...]
Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office
Patent JP6692856 upheld for second time in response to invalidation challenge Dublin, Ireland, 13 December 2023: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 [...]
Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing
Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions Cambridge, UK, 13 December, 2023: Sphere Fluidics, a leading provider of innovative microfluidics-based [...]
SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel
Phase IIa clinical trial evaluated Aurase Wound Gel in patients with venous leg ulcers Former Smith+Nephew CMO, Andy Weymann joins as Chairman to support progression of further Phase II clinical [...]